Physician profile
Michael C Chen
NPI 1114131042
$2,055.47
in general payments reported to CMS, 2019-2025
15 companies · $211 in 2025
The $211 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.02 · 2020: $236 · 2021: $280 · 2022: $598 · 2023: $269 · 2024: $448 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905 · Education: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.60 |
| Education | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.18 | 2020-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $535.31 | 2020-2025 | Otezla, Otezla |
| Pfizer INC. | $263.77 | 2021-2025 | |
| Janssen Biotech, INC. | $123.97 | 2022-2025 | Tremfya |
| Incyte Corporation | $37.58 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $37.20 | 2024 | Neuac |
| Lilly USA, LLC | $26.78 | 2022 | |
| Galderma Laboratories, L.P. | $26.45 | 2022-2025 | Nemluvio |
| Allergan, INC. | $24.26 | 2022 | |
| Ucb, INC. | $17.94 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.84 | 2025 | Ycanth |
| Dermavant Sciences, INC. | $13.41 | 2022 | |
| Boston Scientific Corporation | $13.02 | 2019 | |
| Genzyme Corporation | $13.01 | 2022 | |
| Organogenesis INC. | $12.75 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.